Europe Cardiac Resynchronization Therapy Market Size & Outlook
- MedTech
- Cardiovascular Devices
- Cardiac Resynchronization Therapy Market Outlook
- Cardiovascular Devices
Global Report
Related Markets
Ask a question about the cardiac resynchronization therapy market
Europe cardiac resynchronization therapy market highlights
- The Europe cardiac resynchronization therapy market generated a revenue of USD 1,140.7 million in 2025.
- The market is expected to grow at a CAGR of 6.3% from 2026 to 2033.
- In terms of segment, crt-defibrillator was the largest revenue generating product in 2025.
- CRT-Pacemaker is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 1,140.7 million |
| Market revenue in 2033 | USD 1,864.5 million |
| Growth rate | 6.3% (CAGR from 2026 to 2033) |
| Largest segment | Crt-defibrillator |
| Fastest growing segment | CRT-Pacemaker |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CRT-Defibrillator, CRT-Pacemaker |
| Key market players worldwide | Medtronic PLC, Abbott Laboratories, Boston Scientific Corp, BIOTRONIK, MicroPort Scientific Corp, LivaNova PLC |
Other key industry trends
- In terms of revenue, Europe region accounted for 22.6% of the cardiac resynchronization therapy market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,480.5 million by 2033.
The European cardiac resynchronization therapy market is projected to grow at a notable pace in the coming years. This can be attributed to presence of key market players, high prevalence of heart failure, and well-established healthcare infrastructure.
Significant regional variations in clinical practice were observed. Around 28% of procedures were found to be upgrades from a permanent ICD or pacemaker. Of the CRT devices implanted, 30% were CRT pacemakers and 70% were found to be CRT defibrillators.
No credit card required*
Publish Date: Nov 11, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cardiac Resynchronization Therapy Market Scope
Cardiac Resynchronization Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Medtronic PLC | View profile | 95,000 | Lower Hatch Street, 20 On Hatch, Dublin, Ireland, 2 | www.medtronic.com |
| Boston Scientific Corp | View profile | 48,000 | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 | www.bostonscientific.com |
| LivaNova PLC | View profile | 2,900 | 20 Eastbourne Terrace, London, United Kingdom, W2 6LG | www.livanova.com |
| BIOTRONIK | View profile | 5001-10000 | Berlin, Berlin, Germany, Europe | www.biotronik.com/de-de |
| MicroPort Scientific Corp | View profile | 8,230 | 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai, China, People's Republic of, 201203 | www.microport.com |
Europe Cardiac Resynchronization Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cardiac Resynchronization Therapy Market Outlook will help companies and investors design strategic landscapes.
Crt-Defibrillator was the largest segment with a revenue share of 68.62% in 2025.
Horizon Databook has segmented the Europe cardiac resynchronization therapy market based on crt-defibrillator, crt-pacemaker covering the revenue growth of each sub-segment from 2021 to 2033.
The European cardiac resynchronization therapy market is projected to grow at a notable pace in the coming years. This can be attributed to presence of key market players, high prevalence of heart failure, and well-established healthcare infrastructure.
Significant regional variations in clinical practice were observed. Around 28% of procedures were found to be upgrades from a permanent ICD or pacemaker. Of the CRT devices implanted, 30% were CRT pacemakers and 70% were found to be CRT defibrillators.
- Europe Cardiac Resynchronization Therapy Market Product Outlook (Revenue, USD Million , 2021-2033)
- CRT-Defibrillator
- CRT-Pacemaker
- Europe Cardiac Resynchronization Therapy Market End-Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Cardiac Centers
- Others
Reasons to subscribe to Cardiac Resynchronization Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cardiac Resynchronization Therapy Market Outlook databook
- Our clientele includes a mix of Cardiac Resynchronization Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Cardiac Resynchronization Therapy Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Cardiac Resynchronization Therapy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Cardiac Resynchronization Therapy Market, 2021-2033 (US$M)
Europe cardiac resynchronization therapy market statistics, by product, 2021-2033 (US$M)
